Literature DB >> 22463386

Stem cell factor-displaying simian immunodeficiency viral vectors together with a low conditioning regimen allow for long-term engraftment of gene-marked autologous hematopoietic stem cells in macaques.

Els Verhoeyen1, Francis Relouzat, Marie Cambot, Caroline Costa, Didier Nègre, Faézeh Legrand, Christophe Joubert, Roger Le Grand, François-Loïc Cosset, Philippe Leboulch, Anne Dubart-Kupperschmitt, Stephane Prost.   

Abstract

Although clinical benefits have been reported in several human hematopoietic gene therapy trials, a remaining important goal is the transition to nonmyeloablative pretransplantation conditioning to decrease toxicity. Previous attempts at reduced intensity conditioning in nonhuman primates have resulted in only temporary vector marking of autologous blood cells or their persistence at low levels, well below the thresholds for clinical efficacy. In addition, we reasoned that lentiviral vector particles displaying cytokines at their surface have the potential to preserve stem cell fitness better than current ex vivo transduction protocols, which involve exposure to cytokine overstimulation. Here we show that the classically nonmyeloablative agent fludarabine (30 mg/m(2)/day for 3 days) together with low-level total body irradiation (2 Gy) and the use of a stem cell factor-displaying simian immunodeficiency virus-based vector, resulted in sustained, single-copy vector marking of autologous blood cells in two macaques over 3 years posttransplantation at levels averaging 1% of all lineages. This percentage is within the range of anticipated efficacy levels for hemophilia and related diseases and forms a basis for further improvement.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22463386      PMCID: PMC3404425          DOI: 10.1089/hum.2012.020

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  56 in total

1.  High levels of transduction of human dendritic cells with optimized SIV vectors.

Authors:  Philippe-Emmanuel Mangeot; Karine Duperrier; Didier Nègre; Bertrand Boson; Dominique Rigal; François-Loïc Cosset; Jean-Luc Darlix
Journal:  Mol Ther       Date:  2002-03       Impact factor: 11.454

2.  Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34(+) cells transplanted into conditioned NOD/SCID recipients.

Authors:  Anna Jetmore; P Artur Plett; Xia Tong; Frances M Wolber; Robert Breese; Rafat Abonour; Christie M Orschell-Traycoff; Edward F Srour
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

3.  Differences in megakaryocyte expansion potential between CD34(+) stem cells derived from cord blood, peripheral blood, and bone marrow from adults and children.

Authors:  S van den Oudenrijn; A E von dem Borne; M de Haas
Journal:  Exp Hematol       Date:  2000-09       Impact factor: 3.084

4.  Persistent low-level engraftment of rhesus peripheral blood progenitor cells transduced with the fanconi anemia C gene after conditioning with low-dose irradiation.

Authors:  E M Kang; Y Hanazano; P Frare; E F Vanin; M De Witte; M Metzger; J M Liu; J F Tisdale
Journal:  Mol Ther       Date:  2001-06       Impact factor: 11.454

5.  Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A.

Authors:  D A Roth; N E Tawa; J M O'Brien; D A Treco; R F Selden
Journal:  N Engl J Med       Date:  2001-06-07       Impact factor: 91.245

6.  Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells.

Authors:  M Rosenzweig; M Connole; R Glickman; S P Yue; B Noren; M DeMaria; R P Johnson
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

7.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

Authors:  M Cavazzana-Calvo; S Hacein-Bey; G de Saint Basile; F Gross; E Yvon; P Nusbaum; F Selz; C Hue; S Certain; J L Casanova; P Bousso; F L Deist; A Fischer
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

8.  Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G(2)/M transit and do not reenter G(0).

Authors:  H Glimm; I H Oh; C J Eaves
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

9.  Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells.

Authors:  D Nègre; P E Mangeot; G Duisit; S Blanchard; P O Vidalain; P Leissner; A J Winter; C Rabourdin-Combe; M Mehtali; P Moullier; J L Darlix; F L Cosset
Journal:  Gene Ther       Date:  2000-10       Impact factor: 5.250

Review 10.  The expanding role of fludarabine in hematologic malignancies.

Authors:  M J Keating; S O'Brien; L E Robertson; H Kantarjian; M Dimopoulos; P McLaughlin; F Cabanillas; V Gregoire; Y Y Li; V Gandhi
Journal:  Leuk Lymphoma       Date:  1994
View more
  5 in total

Review 1.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

Review 2.  Development of gene therapy for thalassemia.

Authors:  Arthur W Nienhuis; Derek A Persons
Journal:  Cold Spring Harb Perspect Med       Date:  2012-11-01       Impact factor: 6.915

3.  Measles virus envelope pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without precedent.

Authors:  Camille Lévy; Fouzia Amirache; Anais Girard-Gagnepain; Cecilia Frecha; Francisco J Roman-Rodríguez; Ornellie Bernadin; Caroline Costa; Didier Nègre; Alejandra Gutierrez-Guerrero; Lenard S Vranckx; Isabelle Clerc; Naomi Taylor; Lars Thielecke; Kerstin Cornils; Juan A Bueren; Paula Rio; Rik Gijsbers; François-Loïc Cosset; Els Verhoeyen
Journal:  Blood Adv       Date:  2017-10-24

Review 4.  To condition or not to condition-That is the question: The evolution of nonmyeloablative conditions for transplantation.

Authors:  Anna Rita Migliaccio
Journal:  Exp Hematol       Date:  2016-05-06       Impact factor: 3.084

5.  Induction of Hematopoietic Microchimerism by Gene-Modified BMT Elicits Antigen-Specific B and T Cell Unresponsiveness toward Gene Therapy Products.

Authors:  Jérémie Martinet; Gwladys Bourdenet; Amine Meliani; Laetitia Jean; Sahil Adriouch; Jose L Cohen; Federico Mingozzi; Olivier Boyer
Journal:  Front Immunol       Date:  2016-09-15       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.